Related Experiment Video

Updated: Jun 21, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice

R Pérez-Soler1

  • 1Division of Medical Oncology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. rperezso@montefiore.org

Oncogene
|August 15, 2009
PubMed

Insights

Personalized non-small-cell lung cancer (NSCLC) treatment using genomic and proteomic biomarkers offers improved outcomes. Molecular profiling of NSCLC tumors guides tailored therapies, enhancing efficacy and reducing toxicity for better patient prognoses.

Area of Science:

  • Oncology
  • Genomics
  • Proteomics

Background:

  • Non-small-cell lung cancer (NSCLC) management has seen advances, yet survival improvements with targeted therapies remain marginal.
  • Current treatment strategies for NSCLC often yield poor patient prognoses despite therapeutic progress.
  • Individualized therapy is crucial for optimizing treatment efficacy and minimizing toxicity in NSCLC patients.

Purpose of the Study:

  • To highlight the importance of predictive biomarkers in guiding individualized NSCLC therapy.
  • To explore the role of genomic and proteomic studies in molecular profiling for tailored NSCLC treatments.
  • To underscore the potential of molecular profiling in improving patient outcomes for NSCLC.

Main Methods:

  • Utilizing genomic and proteomic studies for molecular profiling of NSCLC tumor tissue.
  • Analyzing molecular data to identify predictive biomarkers for treatment selection.
  • Applying molecular profiling to tailor therapeutic regimens for individual NSCLC patients.

Main Results:

  • Genomic and proteomic studies enable molecular profiling of NSCLC.
  • This profiling facilitates the tailoring of therapy to individual patient needs.
  • Personalized treatment approaches aim to maximize efficacy and minimize toxicity.

Conclusions:

  • Molecular profiling through genomic and proteomic analysis is key to individualized NSCLC therapy.
  • Identifying predictive biomarkers is essential for improving patient outcomes in NSCLC.
  • Advancements in technology offer hope for overcoming challenges in clinical implementation of these tests.

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...